Results 231 to 240 of about 181,956,994 (291)

Hypervision Proton Surgery: The Future Direction of Proton Therapy

iNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

Enhanced CRISPR‐cas systems for genome editing and molecular diagnostics

Interdisciplinary Medicine, EarlyView.
This review systematically summarizes the major optimization strategies for CRISPR‐Cas systems, focusing on the engineering of Cas proteins, guide RNAs, reporter probes, and the incorporation of chemical additives. The aim is to enhance editing precision and diagnostic capability, thereby expanding the CRISPR system's potential for broader biomedical ...
Sheng Li, Han Li, Bojie Chen, Ling Jiang, Keyu Long, Jiaqi Lang, Xingxiang Pu, Erhu Xiong   +7 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

American Society of Clinical Oncology Statement: Biosimilars in Oncology

Journal of Clinical Oncology, 2018
As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in ...
Gary H, Lyman, Edward, Balaban, Michael, Diaz, Andrea, Ferris, Anne, Tsao, Emile, Voest, Robin, Zon, Michael, Francisco, Sybil, Green, Shimere, Sherwood, R Donald, Harvey, Richard L, Schilsky   +11 more
openaire   +2 more sources

Cancer Prevention and the American Society of Clinical Oncology

Journal of Clinical Oncology, 2004
Scott M. Lippman and Bernard Levin, The University of Texas M. D. Anderson Cancer Center, Houston, TX; Dean E. Brenner, University of Michigan, Ann Arbor, MI; Gary B. Gordon, Abbott Laboratories, Abbott Park, IL; Carolyn R. Aldige, Cancer Prevention and Research Foundation of America, Alexandria, VA; Barnett S.
Scott M, Lippman, Bernard, Levin, Dean E, Brenner, Gary B, Gordon, Carolyn R, Aldige, Barnett S, Kramer, Judy E, Garber, Ernest, Hawk, Patricia A, Ganz, Mark R, Somerfield   +9 more
openaire   +2 more sources